Scilex Holding Company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced launching of co-pay programs for both ZTlido( and ELYXYB with the out-of-pocket costs for its product portfolio for commercially insured patients capped at $25 monthly, with certain eligible patients paying as low as $0. This applies to the Company’s postherpetic neuralgia pain product, ZTlido and migraine product, ELYXYB . Scilex has made significant investments to improve patient affordability and access to its products and continues to build on the Company’s commitment to provide non-opioid pain management products to patients.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SCLX:
- Scilex Holding Company Announces Launching of Co-Pay Programs for Both ZTlido® and ELYXYB® for Commercially Insured Patients and the addition of ELYXYB® to a Multi-State Medicaid Pharmaceutical Purchasing Group to Its Purchasing Pool
- Scilex announces U.S. Bankruptcy Court extends lockup period on shares
- Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend
- Scilex Holding Ends Equity Purchase Deal with Yorkville
- Scilex announces new out-of-pocket costs for commercially insured patients